Lemal Richard, Robin Marie, Ravinet Aurélie, Cacheux Victoria, Guièze Romain, Bay Jacques-Olivier
CHU de Clermont-Ferrand, CHU Estaing, service d'hématologie clinique adulte et de thérapie cellulaire, université d'Auvergne CREaT-EA 7283, Inserm CIC-501, 63000 Clermont-Ferrand, France.
Bull Cancer. 2013 Sep;100(9):897-902. doi: 10.1684/bdc.2013.1792.
Ruxolitinib is a JAK/STAT inhibitor, which has demonstrated clinical benefits in patients with intermediate-2 and high-risk myelofibrosis. Moreover, first results of recent clinical trials show a trend to better overall survival with ruxolitinib, which allows to hope that we will soon be able to change the natural evolution of this poor outcome disease. With such results, ruxolitinib quickly obtained the Food and Drug Administration (FDA) approval in the United States of America. In France, ruxolitinib is now available, allowing its administration to symptomatic myelofibrosis patients.
芦可替尼是一种JAK/STAT抑制剂，已在中危-2和高危骨髓纤维化患者中显示出临床益处。此外，近期临床试验的初步结果显示，使用芦可替尼有总体生存率改善的趋势，这让人们有望很快能够改变这种预后不良疾病的自然病程。基于这些结果，芦可替尼很快在美国获得了美国食品药品监督管理局（FDA）的批准。在法国，芦可替尼现已可供使用，可用于有症状的骨髓纤维化患者。
